RecruitingPhase 2NCT07111507

A Study of Tarlatamab for People With Prostate Cancer

TIDAL: Phase 2 Study of Tarlatamab in Patients With Delta-like Protein 3 (DLL3) Positive Metastatic Prostate Cancer

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

32 participants

Start Date

Jul 31, 2025

Study Type

INTERVENTIONAL

Conditions

Metastatic Prostate Cancer

Summary

The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing tarlatamab — an immunotherapy that helps the immune system find and attack cancer cells — in men with prostate cancer. Tarlatamab targets a protein called DLL3, which is found on some prostate cancer cells. This is an early-phase study to test safety and effectiveness. **You may be eligible if...** - You are 18 years or older with confirmed prostate cancer of any type - You have metastatic disease (cancer that has spread) confirmed by CT, MRI, or bone scan - Your oxygen levels are normal (at least 90% on room air) - You are willing and able to provide informed consent **You may NOT be eligible if...** - Your metastatic disease is only visible on PET scan (not confirmed by CT, MRI, or bone scan) - You have active autoimmune disease requiring systemic treatment - You have had prior tarlatamab or similar bispecific antibody therapy - You have significant lung, heart, or liver problems - You have active brain metastases Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTarlatamab

Patients receive lower dose of tarlatamab on Cycle 1 Day 1 (D1) followed by the full dose on Cycle 1 days 8, 15 and days 1 and 15 for all subsequent cycles.